ALXN 2050 clinical trials

A Phase 2, Randomized, Double‑blind, Placebo‑controlled, Dose‑finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

This study is testing a new medicine, ALXN2050, for adults with kidney diseases called lupus nephritis or IgA nephropathy. Researchers want to see if the medicine can reduce protein in the urine and if it's safe.